top of page

Racura Oncology (ASX RAC), Research and Coverage

racura-oncology-ltd

Racura Oncology Ltd (ASX: RAC) is a cancer drug developer based in Sydney. It was called Race Oncology Limited until December 2025 (Change of Company Name, lodged 9 December 2025). Its lead drug is RC220, a formulation of (E,E)-bisantrene. RC220 is in two Phase 1 trials, one in lung cancer and one in advanced solid tumours. A third trial, in acute myeloid leukaemia, has ethics approval at one hospital (ASX announcement, 18 November 2026). No start had been announced at 19 November 2026. The company has no product on sale. Its loss was A$11.1 million in the year to 30 June 2026 (annual report, lodged 25 August 2026). Cash was A$30.7 million at 30 September 2026 (Appendix 4C, lodged 22 October 2026). Samso had published 5 pieces on the company at 19 November 2026.

ASX code: RAC. Full legal name: Racura Oncology Ltd. Chief Executive Officer and Managing Director: Dr Daniel Tillett. Dr Peter Smith is the executive chair. The other directors are Dr Serge Scrofani and Dr Megan Baldwin, both independent non-executive directors (annual report, lodged 25 August 2026). Racura held A$30.7 million in cash at 30 September 2026. The quarterly cash flow report lists no loan facilities (Appendix 4C, lodged 22 October 2026).

Racura was called Race Oncology Limited until December 2025. Shareholders approved the new name on 24 November 2025, and the ASX used it from 10 December 2025. The code stayed RAC (Change of Company Name, lodged 9 December 2025). Samso's five pieces were published before that date and use the old name.

Racura Oncology's RC220 and its regulatory status

Racura's lead drug is bisantrene. The company has no product on sale. The chair's letter says it received regulatory approval in France in 1988 for acute myeloid leukaemia, a blood cancer shortened to AML. RC220 is Racura's formulation of (E,E)-bisantrene, the form of the molecule the company says is the active one. The company says this form attaches to folded sections of DNA and RNA called G-quadruplexes and reduces the activity of a gene called MYC. It describes MYC as dysregulated, meaning not working normally, in up to 70 per cent of cancers (annual report, lodged 25 August 2026). Racura calls the laboratory work behind that claim preclinical, meaning it was not done in patients (ASX announcement, 12 November 2026).

A Phase 1 trial is the first stage of testing in people. It looks mainly at safety as the dose is raised in steps. A Phase 3 trial is the large trial a drug approval usually rests on. A dose-limiting toxicity is a side effect serious enough to stop the dose going higher. A Safety Review Committee is the group of clinicians that reviews the safety data before each step. Racura's documents call CPACS and HARNESS-1 both Phase 1 and Phase 1a/b.

  • CPACS, advanced solid tumours. Phase 1. RC220 is given with doxorubicin, a chemotherapy from the anthracycline family. Racura says the use of these drugs is limited by damage to the heart, and the trial tests whether the combination is safe. Patients are being enrolled in Australia, Hong Kong and South Korea (ASX announcement, 7 October 2026).
  • HARNESS-1, lung cancer. Phase 1. RC220 is given with osimertinib, an existing drug for non-small cell lung cancer that carries a mutation in a gene called EGFR. The first patient was treated at Monash Health in June 2026 (annual report, lodged 25 August 2026).
  • EMILI, acute myeloid leukaemia. No start had been announced at 19 November 2026. Racura expects the first patient to be enrolled and treated in the first quarter of 2027 (ASX announcement, 18 November 2026). That announcement calls EMILI Phase 2b/3, a label for a trial that joins a mid-stage part to a Phase 3 part. The annual report of 25 August 2026 called it Phase 3.

Racura announced on 24 September 2025 that RC220 had received investigational new drug approval from the Korean Ministry of Food and Drug Safety. That approval allows a trial in people to run in South Korea. It is not approval to sell the drug. The annual report says there is no guarantee the company's products will receive regulatory approvals or be commercialised (annual report, lodged 25 August 2026).

CPACS and HARNESS-1, the two trials that have treated patients

CPACS has cleared its first dose level and is enrolling its second. The first dose level was 40 milligrams of RC220 per square metre of body surface with doxorubicin at 60 milligrams per square metre. No dose-limiting toxicity was seen in the first cycle of combined treatment, and the Safety Review Committee supported a move to 80 milligrams (ASX announcement, 7 October 2026).

The conference poster attached to that announcement lists three patients at a data cut-off of 30 June 2026, two in the first dose group and one in the second. Each had received at least five earlier lines of treatment. One withdrew after the first cycle because of frailty. Two ended treatment when their cancer progressed.

The poster calls the treatment-related side effects in the first dose group clinically manageable. The Grade 3 events it lists for that group are diarrhoea, fatigue, low blood pressure and low blood cell counts. Grade 3 is severe on a scale that runs to 5. One case of Grade 3 diarrhoea was reported as a serious adverse event possibly related to the two drugs, with other possible causes present, and it resolved with treatment. No Grade 4 or 5 events were reported (ASX announcement, 7 October 2026).

The second part of CPACS is designed to measure heart function and early signs of anticancer activity at the highest tolerated dose. The annual report expects dose escalation to finish in the 2027 financial year (ASX announcement, 7 October 2026, and annual report, lodged 25 August 2026).

HARNESS-1 has treated two patients at its lowest dose, 50 milligrams per square metre with osimertinib at 80 milligrams a day. The committee found no dose-limiting toxicity in either patient during the 21-day observation period and cleared a move to 100 milligrams. The first patient had Grade 2 colitis, an inflammation of the bowel, after the observation period. The cause could not be determined and the committee could not exclude a role for RC220, so it asked for a second patient at the same dose. That patient had no colitis symptoms after three doses (ASX announcement, 12 October 2026).

Racura says clearance to raise the dose does not show that RC220 works against lung cancer. It says the result rests on two patients at the lowest dose and that the announcement holds no efficacy data. The trial uses one patient at each of the first three dose levels and at least three at each level after that (ASX announcement, 12 October 2026).

EMILI and the earlier AML trials

EMILI is the trial Racura plans in AML that has returned or resisted treatment, with RC220 given alone. The ethics committee of the Sheba Medical Center in Israel has approved it, subject to minor changes to the consent documents. The hospital's governance approval is still needed before the site can open. Racura's board has approved the start of the trial. The first stage, Phase 2b, is to enrol up to 68 patients and compare doses (ASX announcement, 18 November 2026).

The plan leans on two earlier trials at Sheba, which used an older formulation called RC110. Both were run by the hospital's investigators. Racura reports complete or partial responses in 40 per cent of 10 patients in one trial. In the other, where RC110 was given with two other drugs, it reports a response in 6 of 15 evaluable patients (ASX announcement, 17 November 2026). The company calls them "small, single-centre, non-randomised studies" and says their results do not predict the outcome of EMILI (ASX announcement, 18 November 2026).

Racura reported that RC220 and RC110 delivered equivalent amounts of drug to the bloodstream. The study was nonclinical and used six dogs, each given both formulations. The company says the study did not measure anticancer activity and that the safety and efficacy of RC220 in AML still need to be established (ASX announcement, 17 November 2026).

Racura Oncology cash and funding

Racura has no receipts from customers. Its loss was A$11.1 million in the year to 30 June 2026, up from A$4.8 million. Income was a refund of A$2.8 million under the Australian Government's research and development tax incentive, which pays back part of eligible research spending. Interest added A$0.6 million (annual report, lodged 25 August 2026).

In the September 2026 quarter operations used A$3.5 million. The Appendix 4C, the quarterly cash flow form, divides the cash by that outflow and gives 8.68 quarters of funding. Racura says the cash puts it in a position to fund all committed activities into mid-calendar 2028 (quarterly report and Appendix 4C, lodged 22 October 2026). The annual report expects operating losses to continue until a partnership, licence or acquisition is completed. Racura says the Phase 2b stage of EMILI is funded from existing cash. A move to Phase 3 depends on the Phase 2b results, funding and talks with regulators (ASX announcement, 18 November 2026).

Racura said it had raised a total of A$34.3 million from shareholders through option conversions, private placements and option underwriting (ASX announcement, 16 June 2026). It had 196,068,940 shares on issue at 30 September 2026 (quarterly report, lodged 22 October 2026).

The notice of meeting sets the annual general meeting for 23 November 2026. Its nine resolutions include options for each of the four directors and a selective buy-back of 89,621 shares each from Dr Tillett and Mr Phillip Lynch, whom the annual report lists as a director in the 2025 financial year, for no payment. The notice says the buy-back cancels 179,242 shares issued in error on an exercise of options (notice of meeting, lodged 22 October 2026).

Every Samso piece on Racura Oncology, formerly Race Oncology

5 published pieces as at 19 November 2026, grouped by Samso product. Newest first in each group. Dates are Perth dates.

Samso News

Questions people ask about Racura Oncology (ASX RAC)

What does Racura Oncology do? It develops RC220, a formulation of (E,E)-bisantrene and its lead drug. RC220 is in two Phase 1 trials and a third trial is planned. The company has no product on sale.

What is the Racura Oncology share price? The ASX website shows the RAC share price. This page lists Samso's coverage and has no live price.

What is the latest announcement from Racura Oncology? As at 19 November 2026 the newest item on the ASX list was "Sheba Grants Ethics Approval for EMILI AML Trial", lodged on 18 November 2026. It reports hospital ethics approval for the planned AML trial.

Is Race Oncology now Racura Oncology? Yes. Race Oncology Limited became Racura Oncology Ltd in December 2025. The ASX code is still RAC.

Is Racura Oncology worth looking at? This page gives no buy, sell or hold call, price target or valuation. Two Phase 1 trials have treated patients, and each cleared its first dose level with no dose-limiting toxicity. Those results rest on a handful of patients. Racura says the HARNESS-1 clearance does not show that RC220 works. The AML trial has ethics approval at one hospital. No ASX announcement had reported its start at 19 November 2026. Cash was A$30.7 million at 30 September 2026. It lost A$11.1 million in the year to 30 June 2026 and expects operating losses to continue. Samso has no research workup on Racura Oncology. The Samso News piece of 5 December 2025 is the most recent.

Disclosure

Samso holds no shares in Racura Oncology at 17 November 2026.

This page is general information only.

Depth over hype.

Samso company research pages are independent research commentary for general information only. Nothing on this page is financial product advice, and it does not take into account any reader's objectives, financial situation or needs. Figures are drawn from public sources believed reliable at the stated dates but are not guaranteed, and market-sensitive numbers change daily. Samso or associated parties may hold positions in, or have commercial arrangements with, companies mentioned. Seek professional advice before making investment decisions. © Samso 2026, samso.com.au

Page last reviewed 19 November 2026.

bottom of page